Emerging Trends Influencing The Growth Of The Extended-Release Drugs Market: Pioneer In Epilepsy Treatment Innovation

The Extended-Release Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Extended-Release Drugs Market Size Expected to Be by 2034?
In the past years, there has been a significant expansion in the market size of extended-release drugs. It is predicted to rise from $63.11 billion in 2024 to $70.28 billion in 2025, with a compound annual growth rate (CAGR) of 11.4%. The notable growth during the historic period can be linked to factors such as enhanced patient cooperation, the occurrence of chronic diseases, increased effectiveness, the strategy of patent protection, and the advent of biodegradable implants.

In the ensuing years, the extended-release drugs market is projected to experience a fast-paced expansion. The market size is anticipated to rise to $113.05 billion by 2029, boasting a compound annual growth rate (CAGR) of 12.6%. This predicted growth during the forecast period can be linked back to several factors such as the adoption of personalized medicine strategies, patient-focused drug development, increased prevalence of lifestyle diseases, drug repurposing and global availability of extended-release therapies. Key trends that are anticipated to shape the forecast period are the innovative advancements in pharmaceuticals, emerging improvements in drug delivery systems, progress in nanotechnology, the integration of 3D printing in drug manufacturing, the application of artificial intelligence, and a thrust towards environmental sustainability.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12675

What Are the Emerging Segments Within the Extended-Release Drugs Market?
The extended-release drugs market covered in this report is segmented -

1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

What Long-Term Drivers Are Shaping Extended-Release Drugs Market Trends?
The escalation in chronic health issues is projected to stimulate the expansion of the extended-release drug market. Chronic illnesses are classified as those lasting a year or longer, requiring ongoing medical attention and limiting daily activities. Examples include heart disease, obesity, cancer, and diabetes. Extended-release drug systems aim to provide steady medicinal levels in the body over an extended duration. This ensures a constant therapeutic impact while preventing drug level fluctuations associated with immediate-release drugs. For example, the National Center for Biotechnology Information (NCBI), a US National Library of Medicine, projected in January 2023 that by 2050, the population of individuals 50 years and older with at least one chronic illness will increase by 99.5%, reaching 142.66 million. Given this, the escalating prevalence of chronic illnesses is catalyzing the expansion of the extended-release drug market.

Who Are the Top Competitors in Key Extended-Release Drugs Market Segments?
Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

What Extended-Release Drugs Market Trends Are Gaining Traction Across Different Segments?
The trend of product innovation is making waves in the extended-release drug market, as major players are creating new products to maintain their market status. For example, in July 2022, Zydus Pharmaceuticals (USA) Inc., an American generic pharmaceutical firm, introduced extended-release capsules of Topiramate for epilepsy. The company had prior approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. It holds the distinction of being the first company in the U.S. to secure final approval and introduce this medication. These Topiramate extended-release capsules have been approved for people who experience partial onset or primary generalized tonic-clinic seizures.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Which Regions Are Becoming Hubs for Extended-Release Drugs Market Innovation?
North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Extended-Release Drugs Market?
2. What is the CAGR expected in the Extended-Release Drugs Market?
3. What Are the Key Innovations Transforming the Extended-Release Drugs Industry?
4. Which Region Is Leading the Extended-Release Drugs Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.